S
SANUWAVE Health
An emerging leader in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and…
About SANUWAVE Health
SANUWAVE Health, Inc. operates as a publicly traded medical device company (NASDAQ: SNWV) focused on regenerative medicine. Founded in 2004 and headquartered in Eden Prairie, Minnesota, the company develops and commercializes non-invasive technologies that activate the body's natural healing processes. A significant turning point for the company occurred in 2020 with the acquisition of the UltraMIST® System, which complemented its existing dermaPACE® shockwave device and substantially boosted revenues. This strategic acquisition was followed by a major leadership overhaul in 2023, with Morgan Frank, a principal at the company's largest outside shareholder, Manchester Management, stepping in as CEO to navigate the company away from potential bankruptcy and restructure the management team. His background is in corporate restarts and capital markets.
The company's business model centers on a "razor/razor-blade" strategy, deriving revenue from both the initial sale of its medical devices and the recurring sales of single-use disposables or consumables. For the second quarter of 2025, SANUWAVE reported record revenues of $10.2 million, a 42% increase year-over-year, with consumable sales accounting for $6.4 million. The company markets its products to healthcare professionals and facilities that treat chronic wounds. Its primary market is the advanced wound care sector, addressing conditions like diabetic foot ulcers, pressure ulcers, and venous leg ulcers, a market expected to grow due to an aging population and the increasing prevalence of diseases like diabetes.
SANUWAVE's flagship product is the UltraMIST® System, an FDA-cleared device that promotes wound healing. The technology delivers low-frequency, non-contact ultrasound through a saline mist to the wound site. This process helps cleanse the wound, remove bacteria and dead tissue, reduce inflammation, and stimulate cellular activity and blood flow to accelerate healing, all without direct contact with the wound bed, minimizing patient discomfort. The UltraMIST system accounted for 99% of revenue in Q2 2025, demonstrating its central role in the company's commercial strategy. The company also offers the dermaPACE System, which uses Pulsed Acoustic Cellular Expression (PACE) technology for similar regenerative purposes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2009
- Outcome tier
- Colt$25–100M revenue
News
Open roles
SANUWAVE Health in the Eden Prairie ecosystem
The SANUWAVE Health office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about SANUWAVE Health on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SANUWAVE Health on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

